AlzeCure Pharma
The answer first
Does AlzeCure Pharma beat the market?
Yes, AlzeCure Pharma has beaten the market over the last year.
The ranking · Quality, value and trend combined
Better than 91% of Nordic stocks
- Quality93
- Value38
- Trend89
No. 10 of 195 in healthcare
Expectations in the price
Low expectations
For the share to return about 9% a year from today's price, it is enough that the cash AlzeCure Pharma keeps shrinks about 4% a year for 10 years.
Max for seven days
Follow AlzeCure Pharma with AuroraAurora lets you know at the next report. No card.
Both with dividends. Figures as of 19 November 2026. General analysis, not personal advice.
Follow your thesis
Ask Aurora about AlzeCure Pharma
Your first answer is free, no account needed.
Do you own AlzeCure Pharma, or are you thinking about it?
See it next to the rest of your portfolio, or build your first one with AlzeCure Pharma and a few more. Free, no card.
Super Stock+46.4%In short
- AlzeCure Pharma has risen 189.1% over the past year, including dividends.
- Overall, AlzeCure Pharma ranks better than 91% of Nordic stocks on quality, value and trend.
- The largest fall over the past three years was 84.6%. The price is 44.4% below its peak now.
What do analysts think of AlzeCure Pharma?
Quality, value and trend
Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.
Quality, value and trend together. Better than 91% of Nordic stocks.
No. 10 of 195 in healthcare
High A solid company: it earns well on its money and has healthy finances.
No. 23 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50
- Debt to equityBorrowings divided by equity0.02
- Asset turnoverSales divided by everything the company owns0.69
- Return on equityProfit divided by equity+42.6%
- Cash conversionOperating cash flow divided by profit0.98
The ranking is built on equity ratio, ROA and how steadily profit grows.
Medium Fair price: about the same as a typical Nordic stock.
No. 62 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50
- P/BPrice divided by equity3.8
- P/SPrice divided by sales5.1
- P/EPrice divided by earnings8.9
- P/CFPrice divided by operating cash flow9.1
The ranking is built on P/E, P/B and P/S.
High Tailwind in the share price: it has risen more than most over the last year.
No. 28 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50
- 3 months−6.4%
- 6 months+334.2%
- 9 months+199.5%
- 12 months+189.1%
The ranking is built on 3, 6 and 12–1 months.
Return and risk
Return with dividends reinvested.
The funds that own AlzeCure Pharma
One fund we follow owns AlzeCure Pharma. The share is how much of the fund the stock makes up.
- Sweden1
From the funds' latest known holdings.
About AlzeCure Pharma
AlzeCure Pharma is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 10 employees.
AlzeCure Pharma AB (publ) operates as a pharmaceutical company that develops small-molecule drug therapies for the treatment of severe diseases and conditions that affect the central nervous system. The company is involved in the development of drug candidates based on the NeuroRestore, Alzstatin, and Painless research platforms. Its products pipeline includes ACD856 for the treatment of Alzheimer's disease, sleep disorders, depression, traumatic brain injuries, and Parkinson's disease, which is in phase I clinical trial; ACD857 and ACD680 that are in preclinical trial for the treatment of Alzheimer's disease; ACD440, a TRPV1 antagonist, which is in phase II clinical trial for neuropathic pa…


See the full analysis of AlzeCure Pharma.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
Free forever · No card